SWOG researchers to present practice-changing research at virtual ASCO 2021 SWOG always brings an impressive portfolio of work to the ASCO annual meeting, said SWOG Chair Charles D. Blanke, MD, and this year I m particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing.
Investigators will present 12 abstracts from SWOG-led or co-led studies and 11 abstracts from studies led by other groups within the National Clinical Trials Network (NCTN).
Results from S1216 will be presented orally by study chair Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah. S1216 compared androgen deprivation therapy (ADT) combined with TAK-700 to the standard treatment of ADT with bicalutamide in patients who had metastatic hormone-sensitive prostate cancer. The study found that adding TAK-700 to ADT lengthened median progression-free survival in these patients and improved prostate-specific